Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 8Phase NA 6Phase 3 6Phase 1/2 5Phase EARLY_PHASE1 3Phase 2/3 2

Status

Active not recruiting 2Suspended 1Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Plasma cell 1Genitourinary 1Breast 1

Conditions

Sarcoma 1Rhabdoid Tumor 1Neoplasms 1Multiple Myeloma 1Chordoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Fluorodeoxyglucose F18 × 90 days × Clear all
NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

Phase 1/2 Recruiting
22 enrolled
Breast

Breast Neoplasms

NCT02130492 2026-05-15

A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

Weill Medical College of Cornell University

Phase 1/2 Suspended
30 enrolled
Tumor-Agnostic

Neoplasms

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
162 enrolled
Plasma cell

Multiple Myeloma

NCT01038778 2026-04-13

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
47 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡